Leukemia

Articles

Based on recent study results, investigators recommended TBI plus etoposide for patients older than 4 years of age with high-risk ALL undergoing allogeneic hematopoietic stem cell transplantation. 

TBI Plus Etoposide Prior to HSCT Leads to Improved OS, Lower Relapse Risk in High-Risk Pediatric ALL

The addition of the monoclonal antibody blinatumomab to hyper-CVAD could represent a potential option for extending remission times in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia.

Patients with Ph- B-cell ALL May Benefit From Addition of Blinatumomab to Chemotherapy Combo

Videos

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

Nicholas J. Short, MD, on the Future of ALL and Possibilities for Transplant in These Patients

Short described the importance of the time point of CR outcomes for patients treated as part of an ALL study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Nicholas Short, MD, on the Surprising Significance of CR Outcomes for Patients With ALL After Frontline Therapy

Short discussed currently available assays for MRD detection, blinatumomab treatment, and other implications from an ALL study presented at the 2020 ASH Annual Meeting.

Nicholas Short, MD Discusses MRD-Detection Assays and Blinatumomab for Patients With ALL

Short summarized the NGS-based MRD findings from his ALL study presented at the 2020 ASH Annual Meeting.

Nicholas Short, MD, on Findings from Study Examining NGS-Based MRD Assessment for Patients with ALL

The allogeneic off-the-shelf CD22-directed T-cell product, UCART22, showed early signs of activity and no evidence of unexpected toxicities for adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

Early Signs of Activity and Tolerability Found in Allogeneic Product UCART22 for Patients with Relapsed/Refractory CD22+ B-Cell ALL

For adult patients with relapsed or refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma, a phase 1 clinical trial revealed that crenigacestat (LY3039478) demonstrated little clinical activity at the recommended dose.

Crenigacestat Sees Little Clinical Activity at Recommended Phase 1 Dose in R/R T-ALL/T-LBL

The inherited GATA3 variant rs3824662 was found to strongly influence response to remission induction therapy in childhood acute lymphoblastic leukemia and was also associated with relapse.

Inherited GATA3 Variant rs38245662 Influences Response to Treatment in Childhood ALL

Researchers suggested that a scoring system may aid in determining the appropriate use of HSCT in this patient population.

Acute Lymphoblastic Leukemia | Topics